|
|
Cytokinetics Incorporated (NASDAQ: CYTK) |
|
Price: $74.4400
$0.82 
1.114%
|
| Day's High:
| $75.9800033569336
| Week Perf:
| 2.37 %
|
| Day's Low: |
$ 74.37 |
30 Day Perf: |
-1.59 % |
| Volume (M): |
361,986 |
52 Wk High: |
$ 88.31 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$67.57 |
| Open: |
$74.56 |
52 Wk Low: |
$47.22 |
|
|
| Market Capitalization (Millions $) |
9,832 |
| Shares
Outstanding (Millions) |
132 |
| Employees |
673 |
| Revenues (TTM) (Millions $) |
68 |
| Net Income (TTM) (Millions $) |
-894 |
| Cash Flow (TTM) (Millions $) |
56 |
| Capital Exp. (TTM) (Millions $) |
25 |
Business Description
Cytokinetics Incorporated is a biopharmaceutical company that is dedicated to developing small molecule drugs that can be used to treat a variety of diseases. The company was founded in 1997 and is headquartered in South San Francisco, California. Since its inception, Cytokinetics has focused on developing drugs that can enhance the function of the muscles in the body, with an emphasis on skeletal and cardiac muscle.
Cytokinetics has developed a number of investigational drugs that are intended to improve the function of the heart and skeletal muscles. The company has developed a drug called omecamtiv mecarbil that is intended to improve the contractility of cardiac muscle. This drug is currently being tested in several clinical trials for the treatment of heart failure. Cytokinetics has also developed a drug called reldesemtiv that is intended to improve skeletal muscle function in people with amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
In addition to its investigational drugs, Cytokinetics has developed a number of partnerships with other companies and academic institutions. The company has partnered with companies like Amgen and Astellas to advance and develop its investigational drugs. It has also worked with academic institutions like the University of California, San Francisco and the University of Michigan to further explore the science behind its drug development.
Cytokinetics has received numerous grants and awards for its drug development efforts. In 2013, the company received a grant from the National Institute of Neurological Disorders and Stroke to support the development of reldesemtiv for the treatment of ALS. The company has also been recognized by the California Institute for Regenerative Medicine for its work in developing cell therapy approaches for heart disease.
Overall, Cytokinetics has established itself as a leader in the development of drugs that can improve muscle function in a variety of diseases. Its investigational drugs have the potential to improve patient outcomes and benefit the field of medicine as a whole.
Company Address: 350 Oyster Point Blvd South San Francisco 94080 CA
Company Phone Number: 624-3000 Stock Exchange / Ticker: NASDAQ CYTK
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Thu, Nov 27 2025 2:49 PM UTC
As the landscape of investment continues to shift, long-term shareholders of Cytokinetics, Inc. (NASDAQ: CYTK) and three other notable companies find themselves amid scrutiny that can potentially reshape their portfolios. Grabar Law Office, a firm known for its shareholder advocacy, has made an important announcement concerning ongoing investigations into the actions and per...
|
| Announcement
Published Wed, Oct 29 2025 6:08 PM UTC
Deadline Looms for Cytokinetics Investors: Rosen Law Firm Urges Prompt Legal Action In the mercurial world of biotechnology investment, the fortunes of companies often oscillate in response to scientific breakthroughs, regulatory hurdles, and market dynamics. Amidst this landscape, Cytokinetics, Inc. (NASDAQ: CYTK), a prominent player in muscle biology research and drug deve...
|
| Announcement
Published Thu, Sep 18 2025 3:19 PM UTC
This article examines the recent securities class action lawsuit filed against Cytokinetics, Incorporated (NASDAQ: CYTK), alongside a substantial increase in revenue reported for the second quarter of 2025. While the company demonstrated notable financial growth compared to its industry peers, it simultaneously faces significant legal scrutiny and shrinking market share. Thi...
|
| Shares
Published Tue, Mar 18 2025 8:00 PM UTC
Cytokinetics Strengthens Workforce via Strategic Stock Options Amid Market VolatilitySOUTH SAN FRANCISCO, Calif. March 18, 2025 In a calculated move that underscores its commitment to attracting top-tier talent, Cytokinetics, Incorporated (Nasdaq: CYTK) recently announced the granting of stock options and equity awards to an initial cohort of 13 employees. This decision ma...
|
| Shares
Published Tue, Feb 4 2025 9:00 PM UTC
Cytokinetics Encourages Growth with New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. February 4, 2025: Cytokinetics, Incorporated (Nasdaq: CYTK), a biopharmaceutical company notable for its focus on muscle biology-driven therapeutics, has unveiled a strategic step in its human resource management by granting inducement awards. On Janua...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-7.24 $ |
| Revenues (TTM) |
0.51 $
|
| Cash Flow (TTM) |
0.43 $ |
| Cash |
19.76 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
100,550 |
| Net
Income per Employee (TTM) |
-1,328,383 |
| Receivable Turnover Ratio (TTM) |
5.33 |
| Inventory Turnover Ratio (TTM) |
21.66 |
| Asset Turnover Ratio (TTM) |
0.04 |
|
|
| Per Share |
|
| Earnings (TTM) |
-7.24 $
|
| Revenues (TTM) |
0.51 $ |
| Cash Flow (TTM) |
0.43 $ |
| Cash |
19.76 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| Net Product Revenue |
|
 105.24 % |
of total Revenue |
| Collaboration Revenues |
|
16.42 % |
of total Revenue |
| License and Milestone Revenues |
|
41.57 % |
of total Revenue |
| CN |
|
4.19 % |
of total Revenue |
| Development and Commercial Milestones |
|
34.94 % |
of total Revenue |
| |
On February 13 2024 the Cytokinetics Incorporated provided following guidance
Cytokinetics, Incorporated, a biopharmaceutical company based in South San Francisco, announced today that it will release its fourth quarter financial results on February 27, 2024 at 4:00 PM Eastern Time. The co...
|
|
|
